The aplastic form of renal osteodystrophy

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Bone disease is a common complication of chronic kidney disease (CKD) and renal failure, known for over a century.
• Renal osteodystrophy presents in various forms, including osteitis fibrosa, osteomalacia, mixed uraemic osteodystrophy, and the aplastic (adynamic) lesion.
• The aplastic lesion is characterized by low bone formation without significant osteoid accumulation.

Purpose of the Study:

• To investigate the aetiology, consequences, diagnosis, and management of the aplastic form of renal osteodystrophy.
• To assess the role of aluminium toxicity and parathyroid hormone (PTH) levels in the aplastic bone disease.
• To define diagnostic criteria and evaluate management strategies for aplastic renal bone disease.

Main Methods:

• A prospective, cross-sectional study involving patients on dialysis in three Toronto hospitals.
• Collection and analysis of non-invasive data, including parathyroid hormone (PTH) and aluminium levels.
• Assessment of bone histology to evaluate bone formation and mineralization.

Main Results:

• The aplastic lesion can be associated with high or low aluminium levels, with increased aluminium correlating to poorer prognosis and higher mortality.
• In the absence of aluminium toxicity, low bone formation in the aplastic lesion can be normalized by increasing PTH levels.
• While normalizing bone formation is achievable, its impact on overall morbidity and mortality requires further investigation.

Conclusions:

• Aplastic bone disease in renal failure patients is associated with adverse bone health and survival outcomes.
• Management strategies should address aluminium toxicity when present.
• Increasing PTH levels can effectively correct the bone formation defect in aplastic bone disease, particularly when aluminium is not a factor.